Perspective on the Role of Four Beta-blockers in Heart Failure
- 1 July 2022
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Reviews in Clinical and Experimental Pharmacology
- Vol. 17 (2) , 85-89
Abstract
Background: The current recommendations of the American College of Cardiology/ American Heart Association and a previous Bayesian analysis clearly show a mortality benefit with the use of β- blockers in chronic HF, especially for bisoprolol, carvedilol, and sustained-release metoprolol succinate. Objective: The main objective was to report the evidence on the use of the afore-mentioned β-blockers in subjects with heart failure and to characterize the stages of heart failure in response to the four different β-blockers. Furthermore, it shed light on the patient’s satisfaction and improved quality of life using the afore-mentioned β-blockers in subjects with heart failure. Method: The current perspective presented the clinical outcomes, including hospitalization, morbidity, mortality, patient’s satisfaction, and quality of life, of four beta (β)-blockers, namely bisoprolol, carvedilol, metoprolol succinate, and nebivolol in different stages of heart failure. Results : The use of these three agents should be recommended for all stable subjects with current or previous symptoms of heart failure and heart failure with reduced ejection fraction unless there is any contraindication. The fore-mentioned β-blockers (bisoprolol, carvedilol, and metoprolol succinate) can be initiated early, even in stable and symptom-free (at rest) subjects with heart failure. β-blockers in heart failure should be commenced at small doses and then titrated upward as tolerated to achieve the desired clinical effects on heart rate and symptom control. Conclusion: Cardiologists should weigh the benefit-risk in subjects with heart failure and other coexisting cardiovascular problems such as atrial fibrillation and diabetes.Keywords
This publication has 31 references indexed in Scilit:
- Benefits of blockers in patients with heart failure and reduced ejection fraction: network meta-analysisBMJ, 2013
- Effects of β-blockers on glucose and lipid metabolismCurrent Medical Research and Opinion, 2010
- β-Blocker Use for the Stages of Heart FailureMayo Clinic Proceedings, 2009
- Profile of carvedilol controlled-release: a new once-daily formulation of carvedilolExpert Opinion on Pharmacotherapy, 2006
- Stage B Heart FailureCirculation, 2006
- Managing the Post-Myocardial Infarction Patient with Asymptomatic Left Ventricular DysfunctionCardiology, 2006
- Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)European Heart Journal, 2005
- Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart FailureCirculation, 2002
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996